Skip to content
lifestyle.cosmeticsurgeryinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
MBX Biosciences, Inc.
CORRECTING & REPLACING — MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
March 9, 2026
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
March 9, 2026
MBX Biosciences to Participate in Upcoming March Investor Conferences
February 23, 2026
MBX Biosciences to Participate in Upcoming Investor Conferences
February 13, 2026
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
January 22, 2026
←
Previous Page
1
2